降圧薬の世界市場:治療クラス別(利尿薬、ACE阻害薬、カルシウムチャネル遮断薬、血管拡張薬、ベータアドレナリン遮断薬、その他)、流通経路別(小売薬局、病院薬局、Eコマース、その他)

◆英語タイトル:Antihypertensive Drugs Market by Therapeutic Class (Diuretics, ACE Inhibitors, Calcium Channel Blockers, Vasodilators, Beta-adrenergic Blockers, and Others) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce, and Others Distribution Channel): Global Opportunity Analysis and Industry Forecast, 2019–2026
◆商品コード:AMR20FE071
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2019年12月31日
◆ページ数:222
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,370 ⇒換算¥569,220見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥683,700見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算¥953,470見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、降圧薬の世界市場について調べ、イントロダクション、エグゼクティブサマリー、市場概要、治療クラス別(利尿薬、ACE阻害薬、カルシウムチャネル遮断薬、血管拡張薬、ベータアドレナリン遮断薬、その他)分析、流通経路別(小売薬局、病院薬局、Eコマース、その他)分析、地域別分析、企業概要などを総合的、多面的にまとめております。

・イントロダクション
・エグゼクティブサマリ-
・市場概要
・降圧薬の世界市場:治療クラス別(利尿薬、ACE阻害薬、カルシウムチャネル遮断薬、血管拡張薬、ベータアドレナリン遮断薬、その他)
・降圧薬の世界市場:流通経路別(小売薬局、病院薬局、Eコマース、その他)
・降圧薬の世界市場:地域別
・企業概要
【レポートの概要】

The global antihypertensive market accounted for $22,557 million in 2018, and is expected to reach $28,797 million by 2026, registering a CAGR of 3.1% from 2019 to 2026.
Antihypertensive drugs are employed for the treatment of patients suffering from hypertension. Hypertension is a medical condition, which involves rise in blood pressure in the arteries. Furthermore, the patient suffering from hypertension is highly susceptible to other complications, which include heart failure and aneurysm. Therefore, the treatment of this medical condition requires early diagnosis and management by the use of antihypertensive drugs. Some of the antihypertensive drugs available in the market include beta blockers, calcium channel blockers, and vasodilators. These drugs are prescribed by a physician, and are available in retail stores and hospital pharmacies.
The growth of the global antihypertensive market is driven by surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension is another major factor that fuels the growth of the market. Moreover, increase in geriatric population and sedentary lifestyle act as key drivers of the global market. However, recent patent expirations hinder the growth of the antihypertensive market. Conversely, surge in research related to antihypertensive drugs in emerging economies is expected to offer lucrative opportunities during the forecast period.
The global antihypertensive market size is segmented into therapeutic class, distribution channel, and region. On the basis of therapeutic class, the market is fragmented into diuretics, ACE inhibitors, calcium channel blockers, vasodilators, beta-adrenergic blockers, and others. Depending on distribution channel, it is segregated into retail pharmacy, hospital pharmacy, and e-commerce. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current global antihypertensive market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments
• By Therapeutic Class
o Diuretics
o ACE Inhibitors
o Calcium Channel Blockers
o Beta-adrenergic Blockers
o Vasodilators
o Others

• By Distribution Channel
o Retail Pharmacy
o Hospital Pharmacy
o E-commerce

• By Region
o North America
 U.S.
 Canada
 Mexico
o Europe
 Germany
 France
 UK
 Italy
 Spain
 Rest of Europe
o Asia-Pacific
 Japan
 China
 India
 Australia
 South Korea
 Rest of Asia-Pacific
o LAMEA
 Brazil
 Saudi Arabia
 South Africa
 Rest of LAMEA

List of key players profiled in the report
• Boehringer Ingelheim GmbH
• Merck KGaA
• Johnson and Johnson
• Bayer AG
• Pfizer, Inc.
• Takeda Pharmaceutical Co., Ltd.
• AstraZeneca plc
• Daiichi Sankyo Company
• Sanofi S.A.
• Novartis International AG

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
• Merck
• United Therapeutics Corporation Safe In Breastfeeding

【レポートの目次】

Chapter 1: Introduction

1.1. Report Description
1.2. Key Market Segments

1.2.1. List of Key Players Profiled In The Report

1.3. Research Methodology

1.3.1. Primary Research
1.3.2. Secondary Research
1.3.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Key Findings of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Top Player Positioning

3.2.1. Top Investment Pockets

3.3. Key Forces Shaping Antihypertensive Industry/Market
3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. Surge In Geriatric Population Worldwide
3.4.1.2. Surge In Healthcare Expenditure Worldwide
3.4.1.3. Rise In Prevalence of Hypertension Across The Globe

3.4.2. Restraint

3.4.2.1. Patent Expirations of Blockbuster Drugs

3.4.3. Opportunity

3.4.3.1. High Growth Potential In Developing Economies

3.4.4. Impact Analyses

Chapter 4: Antihypertensive Drugs Market, By Drug Class

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Diuretics

4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis By Country

4.3. Ace Inhibitors

4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis By Country

4.4. Calcium Channel Blockers

4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis By Country

4.5. Beta-Adrenergic Blockers

4.5.1. Key Market Trends, Growth Factors, And Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis By Country

4.6. Vasodilators

4.6.1. Key Market Trends, Growth Factors, And Opportunities
4.6.2. Market Size And Forecast, By Region
4.6.3. Market Analysis By Country

4.7. Others

4.7.1. Key Market Trends, Growth Factors, And Opportunities
4.7.2. Market Size And Forecast, By Region
4.7.3. Market Analysis By Country

Chapter 5: Antihypertensive Drugs Market, By End User

5.1. Overview

5.1.1. Market Size And Forecast

5.2. Retail Pharmacy

5.2.1. Market Size And Forecast, By Region
5.2.2. Market Analysis By Country

5.3. Hospital Pharmacy

5.3.1. Market Size And Forecast, By Region
5.3.2. Market Analysis By Country

5.4. E-Commerce Websites & Online Drug Stores

5.4.1. Market Size And Forecast, By Region
5.4.2. Market Analysis By Country

Chapter 6: Antihypertensive Drugs Market, By Region

6.1. Overview

6.1.1. Market Size And Forecast

6.2. North America

6.2.1. Key Market Trends And Opportunities
6.2.2. Market Analysis, By Country

6.2.2.1. U.S.

6.2.2.1.1. U.S. Market Size And Forecast, By Drug Class
6.2.2.1.2. U.S. Market Size And Forecast, By Distribution Channel

6.2.2.2. Canada

6.2.2.2.1. Canada Market Size And Forecast, By Drug Class
6.2.2.2.2. Canada Market Size And Forecast, By Distribution Channel

6.2.2.3. Mexico

6.2.2.3.1. Mexico Market Size And Forecast, By Drug Class
6.2.2.3.2. Mexico Market Size And Forecast, By Distribution Channel

6.2.3. North America Market Size And Forecast, By Drug Class
6.2.4. North America Market Size And Forecast, By Distribution Channel

6.3. Europe

6.3.1. Key Market Trends And Opportunities
6.3.2. Market Analysis, By Country

6.3.2.1. Germany

6.3.2.1.1. Germany Market Size And Forecast, By Drug Class
6.3.2.1.2. Germany Market Size And Forecast, By Distribution Channel

6.3.2.2. France

6.3.2.2.1. France Market Size And Forecast, By Drug Class
6.3.2.2.2. France Market Size And Forecast, By Distribution Channel

6.3.2.3. Uk

6.3.2.3.1. Uk Market Size And Forecast, By Drug Class
6.3.2.3.2. Uk Market Size And Forecast, By Distribution Channel

6.3.2.4. Italy

6.3.2.4.1. Italy Market Size And Forecast, By Drug Class
6.3.2.4.2. Italy Market Size And Forecast, By Distribution Channel

6.3.2.5. Rest of Europe

6.3.2.5.1. Rest of Europe Market Size And Forecast, By Drug Class
6.3.2.5.2. Rest of Europe Market Size And Forecast, By Distribution Channel

6.3.3. Europe Market Size And Forecast, By Drug Class
6.3.4. Europe Market Size And Forecast, By Distribution Channel

6.4. Asia-Pacific

6.4.1. Key Market Trends And Opportunities
6.4.2. Market Analysis, By Country

6.4.2.1. Japan

6.4.2.1.1. Japan Market Size And Forecast, By Drug Class
6.4.2.1.2. Japan Market Size And Forecast, By Distribution Channel

6.4.2.2. China

6.4.2.2.1. China Market Size And Forecast, By Drug Class
6.4.2.2.2. China Market Size And Forecast, By Distribution Channel

6.4.2.3. India

6.4.2.3.1. India Market Size And Forecast, By Drug Class
6.4.2.3.2. India Market Size And Forecast, By Distribution Channel

6.4.2.4. Rest of Asia-Pacific

6.4.2.4.1. Rest of Asia-Pacific Market Size And Forecast, By Drug Class
6.4.2.4.2. Rest of Asia-Pacific Market Size And Forecast, By Distribution Channel

6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class
6.4.4. Asia-Pacific Market Size And Forecast, By Distribution Channel

6.5. Lamea

6.5.1. Key Market Trends And Opportunities
6.5.2. Market Analysis, By Country

6.5.2.1. Brazil

6.5.2.1.1. Brazil Market Size And Forecast, By Drug Class
6.5.2.1.2. Brazil Market Size And Forecast, By Distribution Channel

6.5.2.2. South Africa

6.5.2.2.1. South Africa Market Size And Forecast, By Drug Class
6.5.2.2.2. South Africa Market Size And Forecast, By Distribution Channel

6.5.2.3. Saudi Arabia

6.5.2.3.1. Saudi Arabia Market Size And Forecast, By Drug Class
6.5.2.3.2. Saudi Arabia Market Size And Forecast, By Distribution Channel

6.5.2.4. Rest of Lamea

6.5.2.4.1. Rest of Lamea Market Size And Forecast, By Drug Class
6.5.2.4.2. Rest of Lamea Market Size And Forecast, By Distribution Channel

6.5.3. Lamea Market Size And Forecast, By Drug Class
6.5.4. Lamea Market Size And Forecast, By Distribution Channel

Chapter 7: Company Profiles

7.1. Astrazeneca Plc

7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance

7.2. Boehringer Ingelheim International Gmbh

7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance

7.3. Daiichi Sankyo Company, Limited

7.3.1. Company Overview
7.3.2. Operating Business Segments
7.3.3. Product Portfolio
7.3.4. Business Performance
7.3.5. Key Strategic Moves And Developments

7.4. Johnson & Johnson

7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance

7.5. Lupin

7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance

7.6. Novartis Ag.

7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance

7.7. Merck & Co., Inc

7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance

7.8. Pfizer Inc.

7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance

7.9. Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories)

7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance
7.9.6. Key Strategic Moves And Developments

7.10. Sanofi

7.10.1. Company Overview
7.10.2. Operating Business Segments
7.10.3. Product Portfolio
7.10.4. Business Performance

List of Tables

Table 01. Global Antihypertensive Drugs Market, By Drug Class, 2018-2026 ($Million)
Table 02. Diuretics Antihypertensive Drugs Market, By Region, 2018–2026 ($Million)
Table 03. Ace Inhibitors Antihypertensive Drugs Market, By Region, 2018–2026 ($Million)
Table 04. Calcium Channel Blockers Antihypertensive Drugs Market, By Region, 2018–2026 ($Million)
Table 05. Beta-Adrenergic Blockers Antihypertensive Drugs Market, By Region, 2018–2026 ($Million)
Table 06. Vasodilators Antihypertensive Drugs Market, By Region, 2018–2026 ($Million)
Table 07. Others Antihypertensive Drugs Market, By Region, 2018–2026 ($Million)
Table 08. Global Antihypertensive Drugs Market, By Distribution Channel, 2018-2026 ($Million )
Table 09. Antihypertensive Drugs Market Revenue For Retail Pharmacy, By Region 2018–2026($Million)
Table 10. Antihypertensive Drugs Market Revenue For Hospital Pharmacy, By Region 2018–2026 ($Million)
Table 11. Antihypertensive Drugs Market Revenue For E-Commerce Websites & Online Drug Stores, By Region 2018–2026 ($Million)
Table 12. Antihypertensive Drugs Market, By Region, 2018-2026 ($Million)
Table 13. North America Antihypertensive Drugs Market Revenue, By Country, 2019–2026 ($Million)
Table 14. U.S. Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 15. U.S. Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 16. Canada Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 17. Canada Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 18. Mexico Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 19. Mexico Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 20. North America Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026($Million)
Table 21. North America Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026($Million)
Table 22. Europe Antihypertensive Drugs Market Revenue, By Country, 2019–2026 ($Million)
Table 23. Germany Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 24. Germany Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 25. France Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 26. France Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 27. Uk Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 28. Uk Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 29. Italy Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 30. Italy Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 31. Rest of Europe Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 32. Rest of Europe Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 33. Europe Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026($Million)
Table 34. Europe Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026($Million)
Table 35. Asia-Pacific Antihypertensive Drugs Market Revenue, By Country, 2019–2026 ($Million)
Table 36. Japan Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 37. Japan Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 38. China Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 39. China Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 40. India Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 41. India Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 42. Rest of Asia-Pacific Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 43. Rest of Asia-Pacific Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 44. Asia-Pacific Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026($Million)
Table 45. Asia-Pacific Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026($Million)
Table 46. Lamea Antihypertensive Drugs Market Revenue, By Country, 2019–2026 ($Million)
Table 47. Brazil Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 48. Brazil Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 49. South Africa Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 50. South Africa Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 51. Saudi Arabia Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 52. Saudi Arabia Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 53. Rest of Lamea Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 54. Rest of Lamea Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 55. Lamea Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026($Million)
Table 56. Lamea Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026($Million)
Table 57. Astrazeneca: Company Snapshot
Table 58. Astrazeneca: Operating Business Segments
Table 59. Astrazeneca: Product Portfolio
Table 60. Boehringer Ingelheim: Company Snapshot
Table 61. Boehringer Ingelheim: Product Business Segments
Table 62. Boehringer Ingelheim: Product Portfolio
Table 63. Daiichi-Sankyo.: Company Snapshot
Table 64. Daiichi-Sankyo.: Operating Business Segments
Table 65. Daiichi-Sankyo.: Product Portfolio
Table 66. J&J: Company Snapshot
Table 67. J&J: Operating Business Segments
Table 68. J&J: Product Portfolio
Table 69. Lupin: Company Snapshot
Table 70. Lupin: Operating Segments
Table 71. Lupin: Product Portfolio
Table 72. Novartis: Company Snapshot
Table 73. Novartis: Operating Business Segments
Table 74. Novartis: Product Portfolio
Table 75. Merck: Company Snapshot
Table 76. Merck: Operating Segments
Table 77. Merck: Product Portfolio
Table 78. Pfizer: Company Snapshot
Table 79. Pfizer: Operating Segments
Table 80. Pfizer: Product Portfolio
Table 81. Sun Pharma: Company Snapshot
Table 82. Sun Pharma: Product Portfolio
Table 83. Sanofi: Company Snapshot
Table 84. Sanofi: Product Portfolio

List of Figures

Figure 01. Global Antihypertensive Drugs Market Segmentation
Figure 02. Top Player Positioning, 2018
Figure 03. Top Investment Pockets
Figure 04. Moderate Bargaining Power of Supplier
Figure 05. Low Bargaining Power of Buyers
Figure 06. Low Threat of Substitutes
Figure 07. High Intensity of Rivalry
Figure 08. Low Threat of New Entrant
Figure 09. World Population Aged 65 And Over (%)
Figure 10. Impact Analyses, Antihypertensive Drugs Market
Figure 11. Comparative Share Analysis of Diuretics Market, By Country, 2018 & 2026 (%)
Figure 12. Comparative Share Analysis of Ace Inhibitors Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)
Figure 13. Comparative Share Analysis of Calcium Channel Blockers Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)
Figure 14. Comparative Share Analysis of Beta-Adrenergic Blockers Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)
Figure 15. Comparative Share Analysis of Vasodilators Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)
Figure 16. Comparative Share Analysis of Others Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)
Figure 17. Comparative Share Analysis of Antihypertensive Drugs Market For Retail Pharmacy, By Country, 2018 & 2026 (%)
Figure 18. Comparative Share Analysis of Antihypertensive Drugs Market For Hospital Pharmacy, By Country, 2018 & 2026 (%)
Figure 19. Comparative Share Analysis of Antihypertensive Drugs Market For E-Commerce Websites & Online Drug Stores, By Country, 2018 & 2026 (%)
Figure 20. U.S. Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 21. Canada Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 22. Mexico Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 23. Comparison of Male Geriatric Population In European Countries, 2017 (Million)
Figure 24. Germany Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 25. France Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 26. Uk Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 27. Italy Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 28. Rest of Europe Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 29. Japan Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 30. China Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 31. India Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 32. Rest of Asia-Pacific Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 33. Brazil Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 34. South Africa Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 35. Saudi Arabia Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 36. Rest of Lamea Antihypertensive Drugs Market, 2018-2026 ($Million)
Figure 37. Astrazeneca: Net Sales, 2016–2018 ($Million)
Figure 38. Astrazeneca: Revenue Share By Region, 2018(%)
Figure 39. Boehringer Ingelheim: Net Sales, 2016–2018 ($Million)
Figure 40. Boehringer Ingelheim: Revenue Share By Segment, 2018 (%)
Figure 41. Boehringer Ingelheim: Revenue Share By Region, 2018(%)
Figure 42. Daiichi-Sankyo: Net Sales, 2016–2018 ($Million)
Figure 43. Daiichi-Sankyo: Revenue Share By Segment, 2018 (%)
Figure 44. Daiichi-Sankyo: Revenue Share By Region, 2018(%)
Figure 45. J&J: Net Sales, 2016–2018 ($Million)
Figure 46. J&J: Revenue Share By Segment, 2018 (%)
Figure 47. J&J: Revenue Share By Region, 2018(%)
Figure 48. Lupin: Net Sales, 2017–2019 ($Million)
Figure 49. Lupin: Revenue Share By Region, 2019(%)
Figure 50. Novartis Ag: Net Sales, 2016–2018 ($Million)
Figure 51. Novartis Ag: Revenue Share By Segment, 2018 (%)
Figure 52. Novartis Ag: Revenue Share By Geography, 2018 (%)
Figure 53. Merck: Net Sales, 2016–2018 ($Million)
Figure 54. Merck: Revenue Share By Segment, 2018 (%)
Figure 55. Merck: Revenue Share By Region, 2018(%)
Figure 56. Pfizer: Net Sales, 2016–2018 ($Million)
Figure 57. Pfizer: Revenue Share By Segment, 2018 (%)
Figure 58. Pfizer: Revenue Share By Region, 2018(%)
Figure 59. Sun Pharma: Net Sales, 2016–2018 ($Million)
Figure 60. Sun Pharma: Revenue Share By Region, 2018(%)
Figure 61. Sanofi: Net Sales, 2016–2018 ($Million)
Figure 62. Sanofi: Revenue Share By Segment, 2018 (%)
Figure 63. Sanofi: Revenue Share By Region, 2018(%)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[降圧薬の世界市場:治療クラス別(利尿薬、ACE阻害薬、カルシウムチャネル遮断薬、血管拡張薬、ベータアドレナリン遮断薬、その他)、流通経路別(小売薬局、病院薬局、Eコマース、その他)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆